Certara, Inc.
CERTHealthcareNASDAQHealth Information Services
Scan Results
Daily timeframeCertara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory. The company carries a $1.18B market cap, placing it firmly in the small-cap category. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes.
Market Cap
$1.18B
Beta
1.41
P/E (TTM)
—
P/E (Fwd)
19.80
EPS (TTM)
$-0.14
EPS (Fwd)
$0.39
ROE
-2.2%
ROA
0.8%
Cash
$184.9M
Total Debt
$301.9M
Free CF
$62.6M
52W Change
-27.6%
Annual Financials
Cash vs Debt
Where CERT stands vs its 150-day and 200-day moving averages
As of the August 13, 2026 close, CERT finished 19.02% above its 150-day moving average ($6.73) and 8.10% above its 200-day moving average ($7.41). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CERT overbought or oversold?
At the August 13, 2026 close, CERT's RSI(14) was 66.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $184.9M in cash, though total debt stands at $301.9M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $62.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -2.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 0.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $335.6M (2022) to $418.8M (2025), reflecting a 25% increase over the period.
As with any equity investment, CERT carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Certara, Inc.'s trajectory.